Thoracic mesenchymal malignant tumors and programmed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas

Kanji Otsubo1 | Hiroki Sakai1 | Hiroyuki Kimura1 | Tomoyuki Miyazawa1 |
Hideki Marushima1 | Koji Kojima1 | Naoki Furuya2 | Masamichi Mineshita2 |
Motohiro Chosokabe3 | Junki Koike3 | Hisashi Saji1

1Departments of Chest Surgery, St. Marianna University School of Medicine, Kawasaki, Japan
2Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
3Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan

Correspondence
Hisashi Saji, Department of Chest Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511 Japan. Email: saji-q@ya2.so-net.ne.jp

Abstract

Background: The current study aimed to evaluate the significance of clinicopathological factors, particularly the immunohistochemistry of programmed cell death ligand-1 (PD-L1), in eight cases each of pulmonary sarcomatoid carcinoma (PSC) and malignant pleural mesothelioma (MPM) at our hospital.

Methods: From January 2004 to December 2020, a total of 16 consecutive patients (eight with PSC and eight with MPM diagnosed via surgical resection or biopsy) were included in this study. After retrospectively reviewing the patient characteristics, the associations between PD-L1 status and age, sex, stage, histological type, and prognosis were investigated.

Results: PD-L1-positive staining was observed in four (50%) PSC cases and one (12.5%) MPM case. Among the four PD-L1-positive PSC cases, two showed high PD-L1 expression in the vimentin-positive sarcomatoid compartment. Moreover, among those with PSC, two survived for about 10 years, whereas the others died within 5 years. No clear correlation was found between PD-L1 expression and prognosis. Among the patients with MPM, four survived for more than 2 years, with the longest being 9 years. Among MPM cases who received nivolumab, one patient with positive PD-L1 staining in the sarcomatoid survived, whereas the other with negative PD-L1 staining did not.

Conclusion: The present study showed that sarcomatoid carcinoma had a higher PD-L1 expression compared to non-small-cell lung cancer and that both PSC and MPM tended to exhibit PD-L1 positivity in the sarcomatoid compartment. Moreover, while immune checkpoint inhibitors may somewhat prolong the prognosis of both tumors, further studies with a larger cohort are necessary to confirm our results.

Keywords
immune checkpoint inhibitor, malignant pulmonary mesothelioma, programmed cell death ligand-1, pulmonary sarcomatoid carcinoma

INTRODUCTION

Pulmonary sarcomatoid carcinoma (PSC) and malignant pulmonary mesothelioma (MPM) are two uncommon histologic subtypes of thoracic malignant tumors that exhibit a mesenchymal pattern and have poor prognosis. In fact, studies have shown that the PSC and MPM have an overall 5-year survival rate of approximately 20% and 10%, respectively.1-3 Although conventional platinum-based chemotherapies have been known to have poor effects in both...
malignant tumors, adequate medications and regimens have yet to be established.

PSC is a rare histologic subtype of non-small-cell lung cancer (NSCLC), accounting for approximately 0.3–1.3% of all lung malignancies. This histologic subtype mostly occurs in male smokers during their sixth and seventh decades. The World Health Organization (WHO) defines PSC as a poorly differentiated NSCLC that contains a sarcoma or sarcomatoid component.4–7 PSC can be histologically classified into five types, namely pleomorphic carcinoma, spindle-cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma, with pleomorphic, spindle-cell, and giant cell carcinoma accounting for most of such subtypes. The poor prognosis of PSC has been attributed to the ineffectiveness of first-line platinum-based chemotherapy.8,9 Moreover, its nonspecific symptoms have often resulted in late-stage diagnosis, with some patients presenting with no indications for surgical resection. Reports have shown that two-thirds of patients with PSC have disease progression on first evaluation, with a mean median survival of 11.0–13.3 months and a 5-year overall survival of approximately 20%.3,7

MPM is another rare yet aggressive malignant tumor originating from the pleura that has been associated with asbestos exposure.1,2,10 MPM can be histologically classified into three types, namely epithelioid, sarcomatoid, and biphasic.11 Notably, evidence has shown that the non-epithelioid type has worse prognosis compared to the epithelioid type. The only approved drug therapy for MPM has been a combination of platinum and a folate antimetabolite, such as pemetrexed. Although bevacizumab, a targeted drug,

| Table 1 | Main clinicopathological characteristics of PSCs |
|---------|-------------------------------------------------|
| Age | Sex | Stage | Smoking | Treatment | Histology | PD-L1 | Survival | Outcome |
| 70 | M | IA | No | Surgery | Sarcomatoid carcinoma | Negative | Alive | Multiple bone metastasis 9 months after surgery |
| 76 | F | IA | No | Surgery | Pleomorphic carcinoma | Positive | Alive | Alive 10 years after surgery |
| 61 | M | IA | Unknown | Surgery | Spindle-cell carcinoma | Positive | Alive | Alive 9 years after surgery |
| 66 | M | IIB | Unknown | Chemotherapy | Pleomorphic carcinoma | Negative | Death | Dead 2 months after diagnosis |
| 75 | M | IIIA | Yes | Surgery | Pleomorphic carcinoma | Positive | Death | Multiple bone metastasis 3 months after surgery |
| 66 | M | IV | Unknown | Radiation | Sarcomatoid carcinoma | Negative | Death | Unknown |
| 90 | M | IV | Yes | Radiation | Pleomorphic carcinoma | Positive | Death | Dead 3 months after diagnosis |
| 79 | M | IV | Yes | BSC | Giant cell carcinoma | Negative | Death | Dead 2 months after diagnosis |

Abbreviations: BSC, best supportive care; F, female; M, male.

| Table 2 | Main clinicopathological characteristics of MPMs |
|---------|-------------------------------------------------|
| Age | Sex | Stage | Surgery | Chemotherapy | Histology | PD-L1 status | Survival | Outcome |
| 71 | M | IA | Intrathoracic debridement | First: CDDP plus PEM 2 courses Second: nivolumab (PD) | Epithelioid type | Negative (Figure 2a,b) | Alive (4 years) | Best supportive care 3 years after surgery |
| 71 | M | IA | Biopsy | First: CDDP plus PEM 2 courses Second: nivolumab (PR) | Epithelioid type | Positive (Figure 2c,d) | Alive (2 years) |
| 53 | F | IA | Total pleural pneumonectomy | CDDP plus PEM 2 courses | Epithelioid type | Negative | Alive (9 years) |
| 57 | M | IA | Total pleural pneumonectomy | CDDP plus PEM 2 courses (NAC) | Epithelioid type | Negative | Alive (7 years) Recurrence 6 years after surgery followed by PEM |
| 62 | M | IB | Total pleural pneumonectomy | CDDP plus PEM 2 courses | Epithelioid type | Negative | Death (1 year) Respiratory failure due to pleural effusion |
| 78 | M | IB | Biopsy | CDDP plus PEM | Biphasic type | Negative | Death (3 months) Respiratory faille due to pleural effusion |
| 71 | M | IB | Total pleural pneumonectomy | CDDP plus PEM 2 courses | Epithelioid type | Negative | Death (2 months) Dead 2 months after surgery |
| 62 | M | IIIA | Total pleural pneumonectomy | CDDP plus PEM 2 courses | Epithelioid type | Negative | Death (5 months) Respiratory failure due to pleural effusion |

Abbreviations: CDDP, cisplatin; F, female; M, male; NAC, neoadjuvant chemotherapy; PD, partial disease; PEM, pemetrexed sodium hydrate; PR, partial response.
has been added to the regimen, its usage varies by region. Nonetheless, long-term survival with chemotherapy remains poor. Recently, immune checkpoint inhibitors (ICIs), such as programmed cell death ligand-1 (PD-L1) inhibitors, have dramatically improved the prognosis of lung carcinoma. Several reports examining PD-L1 positivity in PSC have

FIGURE 1  Immunohistochemistry of pulmonary sacomatoid carcinoma. (a)–(d) and (e)–(h) are the same specimen. (a) and (e) show hematoxylin–eosin staining, (b) and (f) show cytokeratin AE1/AE3 immunohistochemistry, (c) and (g) show vimentin immunohistochemistry, and (d) and (f) show programmed cell death ligand-1 (PD-L1) immunohistochemistry. (a)–(d) show PD-L1 expression in the vimentin-positive sarcomatoid area, while (e)–(h) show PD-L1 expression in the vimentin-negative epithelioid area. The lower left quarter of each image is an enlarged image of the PD-L1 negative part, which is composed of atypical cells with a high nuclear/cell ratio and different sizes, indicating that it is tumor

OTSUBO ET AL.
suggested that the presence or absence of PD-L1 determined via immunohistochemistry can predict the effects of PD-L1 inhibitors. According to the aforementioned studies, PSC has higher PD-L1 positivity rates compared to conventional NSCLC, suggesting that PD-L1 inhibitors may be an optimal treatment for PSC. Meanwhile, clinical trials on MPM have indicated the therapeutic effect of a combination therapy comprising anti-PD-L1 antibody and anti-cytotoxic T-lymphocyte associated antigen (CTLA) antibody. However, several studies have reported that the PD-L1 positivity rate does not aid in the prediction of the therapeutic effect of this combination therapy. The current study therefore aimed to evaluate the significance of the clinico-pathological factors, including the immunohistochemistry of PD-L1, in eight cases each of PSC and MPM at our hospital.

**METHODS**

**Patients**

This study included consecutive patients with PSC or MPM diagnosed via surgical resection or biopsy at St. Marianna University School of Medicine Hospital from January 2004 to December 2020. The follow-up period lasted as long as medical records existed, with the maximum duration being 10 years. The histopathological diagnosis was confirmed by two pathologists (JK and MC) according to the current 2015 WHO classification of lung tumor. The clinical characteristics, surgical staging, tumor-node-metastasis staging (8th edition), treatments, and outcomes were collected from the medical records. This study was approved by the
Institutional review board of the St. Marianna University School of Medicine in Kanagawa, Japan (Accession No. 1461). Prior to study initiation, written informed consent was obtained from all participants. All patient data remained confidential throughout this research.

Immunohistochemistry

To measure PD-L1 expression, this study used a murine anti-PD-L1 monoclonal antibody (E1L3N; Cell Signaling). Briefly, serial 3-μm thick tissue sections were cut from formalin-fixed, paraffin-embedded blocks. Antigen retrieval was performed in a 97°C water bath for 15 min in pH 9 solution. Intrinsic peroxidase activity was blocked using hydrogen peroxide for 10 min. After washing the section with a phosphate buffer solution, automated immunohistochemistry was conducted (Histostainer 48A; Nichirei Bioscience Inc.). The PD-L1 antibody dilution was 1:400. PD-L1 expression was calculated as the percentage of complete or partial membrane staining in a section that included at least 100 viable tumor cells. Positive and negative expressions of PD-L1 were defined as >1% and <1% staining of the tumor cell membrane, respectively.

To measure vimentin expression, we used a murine antivimentin monoclonal antibody (clone V9 Link; Dako). Briefly, serial 3-μm thick tissue sections were cut from formalin-fixed, paraffin-embedded blocks, deparaffinized in xylene, and rehydrated through a graded series of ethanol concentrations. Antigen retrieval was performed in a 97°C water bath for 15 min in pH 9 solution. Intrinsic peroxidase activity was blocked using hydrogen peroxide for 5 min. After washing the section with a phosphate buffer solution, automated immunohistochemistry was conducted (Histostainer 48A; Nichirei Bioscience Inc). The vimentin antibody dilution was 1:2. Positive and negative vimentin expressions were defined as >50% and <1% staining of tumor cell membrane, respectively.

RESULTS

Patient characteristics

A total of eight consecutive patients were pathologically diagnosed with PSC based on surgical tissue or biopsy samples (Table 1). The median age at diagnosis was 72.5 years old. Among such patients, seven were male (87.5%), and three, one, one, and three had stage I (37.5%), stage II (12.5%), stage III (12.5%), and stage IV (37.5%) disease, respectively. Moreover, three (37.5%) were smokers, two were never smokers, and the rest had unknown smoking history. Pleomorphic carcinoma (50%) was the most frequently identified subtype, with one case having spindle-cell carcinoma and another having giant cell carcinoma. The other tumors were unclassifiable.

A total of eight consecutive patients were pathologically diagnosed with MPM based on surgical tissue or biopsy samples (Table 2). The median age at diagnosis was 66.5 years old.
Among such patients, seven (87.5%) were male, and seven and one presented with stage I (87.5%) and stage III (12.5%) disease at the time of diagnosis, respectively. Seven cases were identified as epithelial type, whereas the remaining were sarcomatoid type.

**Pathological findings and PD-L1 status**

Among cases with PSC, four (50%) had PD-L1-positive staining in the tumor cells. Among these four cases, two showed high PD-L1 expression. Moreover, three cases, two of which had high PD-L1 expression, were PD-L1-positive only in the vimentin-positive sarcomatoid compartment, whereas the remaining case was PD-L1-positive in the epithelial areas (Figure 1). A comparison with reported studies on PD-L1 expression in PSC is provided in Table 2.

Among cases with MPM, one (12.5%) had PD-L1-positive staining in the tumor cell. This particular case had highly positive PD-L1 expression (Figure 2). After two courses of cisplatin (CDDP) plus pemetrexed (PEM) as postoperative chemotherapy, this case received nivolumab and subsequently achieved partial response, whereas another case with negative PD-L1 expression received nivolumab as second-line chemotherapy, but terminated due to progressive disease. A comparison between previously reported studies on PD-L1 expression in MPM is provided on Table 3.

**Survival**

Follow-up lasted for as long as medical records were available. Among those with PSC, two survived for approximately 10 years, whereas the remaining who had poor prognosis died within 5 years after some metastasis. No clear correlation was found between PD-L1 expression and prognosis. Among those with MPM, four survived for more than 2 years, with the longest being 9 years. All four cases had stage I disease on diagnosis.

**DISCUSSION**

Previous studies have shown high PD-L1 positive rates ranging from 36.5% to 90.2% in PSC. Consistent with previous studies, the current study found that four patients (50%) presented positive for PD-L1. A comparison of published studies regarding the immunohistochemistry of PD-L1 in PSC is provided in Table 3. According to these studies, anti-PD-1/PD-L1 treatment may demonstrate potential therapeutic effects against PSCs, but the solid evidence has not yet been established. Moreover, PD-L1 tended to be positive in the sarcomatoid part of PSC, which was the vimentin-positive area. Consistent with a previous study, the current study showed that three of the four cases with PD-L1-positive PSC showed positivity in the vimentin-positive sarcomatoid area.

Meanwhile, nivolumab plus ipilimumab has been approved as a first-in-class regimen for unresectable MPM in the USA. However, studies regarding the association between PD-L1 expression and dual ICI efficacy have been inconsistent. Our study showed that nivolumab administered as a second-line treatment successfully treated our single sample of epithelioid type MPM that showed positive expression of PD-L1 (Figure 2c,d), inconsistent with previous studies. Therefore, only two patients underwent ICI as a second-line treatment at our institution and one of them showed therapeutic effect and positive for PD-L1; performing ICI in other cases could have possibly prolonged their prognosis as well. Non-epithelioid cell types have been reported to have a poor prognosis. Consistent with previous studies, our study showed that our single case presenting with biphasic histology died 3 months after surgery. According to the phase 3 trial of Baas et al., the effect of the dual ICI can be expected even in the nonepithelioid type with poor prognosis. It can be said that the nonepithelioid type, which consists of sarcomatoid and biphasic types, has interstitial properties. In addition, it has been reported that vimentin, which is a medium-diameter filament peculiar to stromal cells, is positive in MPM in 57–71% of cases. Since all eight cases in this study were positive for vimentin, it is considered that all of them had interstitial properties regardless of histologic subtypes. In this study, the patient who only obtained partial response by the second-line treatment of nivolumab also had an epithelial type of MPM, but we speculate that the partial response may be due to positivity of vimentin and interstitial properties. While a previous study showed that stage III and higher disease stages accounted for approximately 70%, only one case in the current study was stage III, whereas the other cases were stage I. Some cases can achieve long-term survival of 7 or 9 years, which has formed the basis for supporting the effectiveness of early detection and surgery.

Our study showed that there is no relationship between PD-L1 positivity and survival in PSC, while ICI chemotherapy may improve the prognosis of PD-L1-positive cases in MPM, since the only case which was positive for PD-L1 was improved by ICI chemotherapy. In both PSC and MPM, early clinical stage tended to result in better survival.

Thoracic mesenchymal malignant tumors such as MPM and PSC tend to have “mesenchymal” characteristics, such as having a sarcomatoid morphology or having vimentin, a medium-diameter filament peculiar to stromal cells, in the cytoskeleton. In this study, it was shown that having this “interstitial” property may be related to the expression of PD-L1 and the effect of ICI. Although MPM has already shown the effectiveness of ICI containing nivolumab, evidence of anti-PD-1/PD-L1 inhibitor has not yet been established in PSC. Considering these reasons, it can be expected that ICI containing anti-PD-1/PD-L1 inhibitor also will be effective in PSC if it has interstitial properties similar to MPM. For the treatment of PSC and MPM, combination therapy of multiple drugs, including ICI, has been utilized. Recently, several groups have reported on cluster of differentiation 47 (CD-47), a protein highly expressed in small-cell lung carcinoma that helps tumors to avoid immunity. Yang et al. suggested that PD-L1/CD47 co-expression was an
CONCLUSIONS

After evaluating eight cases each of PSC and MPM at our hospital, the current study found that SCs had higher PD-L1 expression compared to NSCLC and that PD-L1 expression tended to occur in the sarcomatoid compartment of both PSC and MPM. Moreover, ICI can prolong the prognosis of both tumors to some extent. Furthermore, combined ICI therapy containing anti-PD-L1 antibody and other immuno-therapies or anti-angiogenesis inhibitors is expected to further improve prognosis. To establish new combination therapies, other oncogene mutations need to be identified.

ACKNOWLEDGMENTS

English editing assistance was provided by Crimson Interactive Pvt. Ltd.

CONFLICT OF INTEREST

All authors have declared no competing interests for this study.

ORCID

Kanji Otsubo https://orcid.org/0000-0003-4978-4988
Hideki Marushima https://orcid.org/0000-0002-9865-498X
Naoki Furuaya https://orcid.org/0000-0001-7162-5946
Masamichi Minessita https://orcid.org/0000-0002-6933-6579
Hisashi Saji https://orcid.org/0000-0003-3490-7658

REFERENCES

1. Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010;5:1841–8.
2. Van Gerwen M, Alpert N, Wolf A, Ohri N, Lewis E, Rosenzweig KE, et al. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database. Carcinogenesis. 2019;40:529–36.
3. Huang SY, Shen SJ, Li XY. Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases. World J Surg Oncol. 2013;11:252.
4. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60.
5. Yuki T, Sakuma T, Ohbayashi C, Yoshimura M, Tsubota N, Okita Y, et al. Pleomorphic carcinoma of the lung: a surgical outcome. J Thorac Cardiovasc Surg. 2007;134:399–404.
6. Martin LW, Correa AM, Ordonez NG, Roth JA, Swisher SG, Vapourciyan AA, et al. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg. 2007;84:973–80.
7. Venisss N, Pop D, Lassalle S, Berthier F, Hofman P, Mouroux J. Sarcomatoid lung cancer (spindle/giant cells): an aggressive disease? J Thorac Cardiovasc Surg. 2007;134:4619–23.
8. Giroux Leprieur E, Antoine M, Vieira T, Duruisseaux M, Poulot V, Rabbe N, et al. Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy. Lung Cancer. 2013;79:167–72.
9. Vieira T, Girard N, Ung M, Monnet I, Cazes A, Bonnette P, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol. 2013;8:1574–7.
10. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008;9:147–57.
11. Bille A, Krug LM, Woo KM, Rusch VW, Zauderer MG. Contempo- rary analysis of prognostic factors in patients with unselectable malign- nant pleural mesothelioma. J Thorac Oncol. 2016;11:249–55.
12. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–14.
13. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Cosszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.
14. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:243–54.
15. Naito M, Tamiya A, Takeda M, Taniguchi Y, Saio N, Naoki Y, et al. A high PD-L1 expression in pulmonary pleomorphic carcinoma correlates with parietal-pleural invasion and might predict a poor prog- nosis. Intern Med. 2019;58:921–7.
16. Velchetti V, Riml DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol. 2013;8:803–5.
17. Vieira T, Antoine M, Hamard C, Fallet V, Duruisseaux M, Rabbe N, et al. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer. 2016;98:51–8.
18. Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhhorst K, de Vries JF, van der Noort V, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7:260–70.
19. Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13:1569–76.
20. Calabrò L, Morra A, Giannarelli D, Amato G, D’Incecco A, Covre A, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6:451–60.
21. Yang Z, Xu J, Li R, Gao Y, He J. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. J Cancer Res Clin Oncol. 2019;145:3055–65.

22. Yvorel V, Patoir A, Casteillo F, Tissot C, Fournel P, Stachowicz ML, et al. PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. PLoS One. 2017;12:e0180346.

23. Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, et al. Programmed death-ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas. Eur J Cancer. 2015;51:2698–707.

24. Domblides G, Leroy K, Monnet I, Mazieres J, Barlesi F, Gounant V, et al. Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma. J Thorac Oncol. 2020;15:860–6.

25. Kotlowska MP, Rueda AG, Olmedo ME, Benito A, Roldan AS, Fernandez Mendez MA, et al. Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review. Respir Med Case Rep. 2019;26:310–4.

26. Senoo S, Ninomiya T, Makimoto G, Nishii K, Kano H, Watanabe H, et al. Rapid and long-term response of pulmonary pleomorphic carcinoma to pembrolizumab: a case report. Case Rep Oncol. 2019;12:752–7.

27. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375–86.

28. Hiroshi Izumi TK, Miyamoto H, Yamazaki A, Uekusa T. Immunohistochemical studies of malignant pleural mesothelioma using the mesothelium-related antigens. Jpn J Lung Cancer. 2000;40:711–7.

29. Mayall FG, Goddard H, Gibbs AR. Intermediate filament expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon. Histopathology. 1992;21:453–7.

30. CB MDG-P, Sotelo T, Lopez-Encuentra A, Mayordomo II. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. Histopathology. 1998;32:462–72.

31. Xiao Z, Chung H, Banan B, Manning PT, Ott KC, Lin S, et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett. 2015;360:302–9.

32. Yoshida K, Tsujimoto H, Matsumura K, Kinoshita M, Takahata R, Matsumoto Y, et al. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med. 2015;4:1322–33.

33. Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest. 2016;126:2610–20.

34. Jin C, Yang B. Dramatic response of pulmonary sarcomatoid carcinoma to nivolumab combined with anlotinib: a case report. Case Rep Oncol. 2020;13:601–5.

35. Liang H, Wang M. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. Cancer Manag Res. 2019;11:7707–19.

36. Ugurluer G, Chang K, Gamez ME, Arnett AL, Jayakrishnan R, Miller RC, et al. Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma. Anticancer Res. 2016;36:2331–8.

37. Pecuchet N, Vieira T, Rabbe N, Antoine M, Blons H, Cadranel J, et al. Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities. Ann Oncol. 2017;28:1597–604.

38. Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34:794–802.

How to cite this article: Otsubo K, Sakai H, Kimura H, Miyazawa T, Marushima H, Kojima K, et al. Thoracic mesenchymal malignant tumors and programmed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas. Thorac Cancer. 2021;12:3169–76. https://doi.org/10.1111/1759-7714.14177